Walton, Michael I <br/><br/>
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.  [electronic resource] 

 -  Molecular cancer therapeutics  Jan 2010 
 - 89-100 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-09-0938  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Biomarkers, Tumor--metabolism<br/>Camptothecin--administration & dosage<br/>Cell Death--drug effects<br/>Cell Line, Tumor<br/>Checkpoint Kinase 1<br/>DNA Damage<br/>Deoxycytidine--administration & dosage<br/>Drug Synergism<br/>G2 Phase--drug effects<br/>Humans<br/>Irinotecan<br/>Isoquinolines--administration & dosage<br/>Mice<br/>Mice, Nude<br/>Mutagens--toxicity<br/>Phosphorylation--drug effects<br/>Protein Kinase Inhibitors--administration & dosage<br/>Protein Kinases--metabolism<br/>Pyrazines--administration & dosage<br/>Xenograft Model Antitumor Assays<br/>Gemcitabine